What is Response Biomedical?
Founded in 1992 and headquartered in British Columbia, Canada, Response Biomedical Corp. specializes in the development, manufacturing, and commercialization of the RAMP system. This rapid diagnostics platform is engineered to provide high-performance, lab-quality results, facilitating more efficient patient management in acute care settings. By bridging the gap between traditional laboratory testing and immediate clinical decision-making, the company addresses critical bottlenecks in emergency medicine and critical care workflows. Its market position is characterized by a focus on diagnostic precision, operational efficiency, and the integration of advanced biosensor technology into clinical practice.
How much funding has Response Biomedical raised?
Response Biomedical has raised a total of $22.2M across 5 funding rounds:
Private Equity
$3.9M
Private Equity
$7.7M
Private Equity
$4.9M
Private Equity
$3.1M
Other Financing Round
$2.5M
Private Equity (2009): $3.9M, investors not publicly disclosed
Private Equity (2010): $7.7M, investors not publicly disclosed
Private Equity (2011): $4.9M, investors not publicly disclosed
Private Equity (2013): $3.1M, investors not publicly disclosed
Other Financing Round (2014): $2.5M backed by Silicon Valley Bank
Key Investors in Response Biomedical
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, private wealth management, brokerage and investment services, funds management, and business valuation services. The company was founded in 1983 and is headquartered in Santa Clara, California.
What's next for Response Biomedical?
With the recent infusion of capital, Response Biomedical is well-positioned to accelerate its market penetration and enhance its RAMP system capabilities. The strategic focus will likely shift toward expanding the diagnostic menu of the platform and optimizing supply chain logistics to support broader clinical adoption. As the firm navigates the complexities of the diagnostic market, the emphasis will remain on scaling production to meet the increasing demand for rapid, reliable patient data. Future growth will be contingent upon the company's ability to maintain its technological lead while navigating the evolving regulatory and competitive landscape of the global healthcare diagnostics industry.
See full Response Biomedical company page
